In informal practice, patients run BPC-157 in 4 to 8 week cycles, dosed 250 to 500 mcg subcutaneous twice daily or 500 to 750 mcg oral daily, while continuing weekly semaglutide on the standard titration schedule
Thus, conservative management should be used in these patients as well
Men with a personal or strong family history of medullary thyroid cancer should avoid GLP-1 agonists due to animal study signals, though human data remain reassuring
The appetite suppression effect often begins within the first week or two, though significant weight loss typically becomes noticeable around weeks 4 to 8
Overcome portion control & late-night snacking with ease
However, it is encouraging that preclinical and early human studies suggest that GLP-1 agonism appears broadly protective: indeed clinical trials of these agents are being initiated in cardiovascular disease (SELECT and SOUL trials, see below), NASH, and neurodegeneration (Alzheimers and Parkinsons)